MA55390A1 - Dispositif pour découper l'adn à base de la protéine cas9 à partir de la bactérie pasteurella pneumotropica - Google Patents

Dispositif pour découper l'adn à base de la protéine cas9 à partir de la bactérie pasteurella pneumotropica

Info

Publication number
MA55390A1
MA55390A1 MA55390A MA55390A MA55390A1 MA 55390 A1 MA55390 A1 MA 55390A1 MA 55390 A MA55390 A MA 55390A MA 55390 A MA55390 A MA 55390A MA 55390 A1 MA55390 A1 MA 55390A1
Authority
MA
Morocco
Prior art keywords
cas9
cas9 protein
bacterium
dna based
pneumotropica
Prior art date
Application number
MA55390A
Other languages
English (en)
Other versions
MA55390B1 (fr
Inventor
Konstantin Viktorovich Severinov
Daria Nikolaevna Artamonova
Olga Sergeevna Musharova
Tatiana Olegovna Artamonova
Sergey Anatolievich Shmakov
Ignaty Igorevich Goryanin
Julia Valerevna Andreeva
Tatiana Igorevna Zyubko
Yana Vitalievna Fedorova
Mikhail Alekseevich Khodorkovskii
George Evgenevich Pobegalov
Anatoliy Nikolaevich Arseniev
Polina Anatolevna Selkova
Aleksandra Andreevna Vasilieva
Marina Viktorovna Abramova
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Priority claimed from PCT/RU2020/050137 external-priority patent/WO2020251413A1/fr
Publication of MA55390A1 publication Critical patent/MA55390A1/fr
Publication of MA55390B1 publication Critical patent/MA55390B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La présente invention concerne une nouvelle nucléase bactérienne du système crispr-cas9 à partir de la bactérie p. Pneumotropica, ainsi que son utilisation pour former des ruptures strictement spécifiques à deux brins dans la molécule d'adn. Cette nucléase possède des propriétés inhabituelles et peut être utilisée en tant qu'instrument pour apporter des modifications dans des endroits strictement déterminés de l'adn génomique d'organismes unicellulaires ou pluricellulaires. Il est ainsi possible d'améliorer l'universalité de systèmes disponibles crispr-cas9, ce qui permet d'utiliser les nucléases cas9 provenant de différents organismes pour découper l'adn génomique ou plasmidique dans une grande quantité de sites spécifiques et dans diverses conditions.
MA55390A 2019-04-23 2020-06-30 Dispositif pour découper l'adn à base de la protéine cas9 à partir de la bactérie pasteurella pneumotropica MA55390B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2019112296A RU2734432C1 (ru) 2019-04-23 2019-04-23 Моноклональное антитело, которое специфически связывается с GITR
PCT/RU2020/050137 WO2020251413A1 (fr) 2019-06-11 2020-06-30 Dispositif pour découper l'adn à base de la protéine cas9 à partir de la bactérie pasteurella pneumotropica

Publications (2)

Publication Number Publication Date
MA55390A1 true MA55390A1 (fr) 2022-05-31
MA55390B1 MA55390B1 (fr) 2022-10-31

Family

ID=69821666

Family Applications (2)

Application Number Title Priority Date Filing Date
MA54969A MA54969B2 (fr) 2019-04-23 2020-04-23 Anticorps monoclonal se liant spécifiquement à gitr
MA55390A MA55390B1 (fr) 2019-04-23 2020-06-30 Dispositif pour découper l'adn à base de la protéine cas9 à partir de la bactérie pasteurella pneumotropica

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA54969A MA54969B2 (fr) 2019-04-23 2020-04-23 Anticorps monoclonal se liant spécifiquement à gitr

Country Status (24)

Country Link
US (1) US12410257B2 (fr)
EP (1) EP3964525A4 (fr)
JP (1) JP7695200B2 (fr)
KR (1) KR20220010501A (fr)
CN (1) CN110903392B (fr)
AR (1) AR118763A1 (fr)
AU (1) AU2020261207A1 (fr)
BR (1) BR112021021281A2 (fr)
CA (1) CA3137822A1 (fr)
CL (1) CL2021002792A1 (fr)
CO (1) CO2021014153A2 (fr)
EA (1) EA202192907A1 (fr)
IL (1) IL287531A (fr)
JO (1) JOP20210286A1 (fr)
MA (2) MA54969B2 (fr)
MX (1) MX2021012962A (fr)
MY (1) MY210018A (fr)
PE (1) PE20220144A1 (fr)
PY (1) PY2018606A (fr)
RU (1) RU2734432C1 (fr)
TW (1) TWI803718B (fr)
UY (1) UY38672A (fr)
WO (1) WO2020218951A2 (fr)
ZA (1) ZA202109374B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2724470C1 (ru) * 2019-11-11 2020-06-23 Автономная некоммерческая образовательная организация высшего образования Сколковский институт науки и технологий Применение cas9 белка из бактерии pasteurella pneumotropica для модификации геномной днк в клетках
CN111732658B (zh) * 2020-06-28 2022-04-26 英诺湖医药(杭州)有限公司 一组gitr单克隆抗体及其医药用途
CN112540179B (zh) * 2020-08-06 2023-07-07 武汉天德生物科技有限公司 一种测试ApoE4蛋白含量的ELISA试剂盒
CN112362876B (zh) * 2020-08-06 2023-12-15 武汉天德生物科技有限公司 一种检测早期老年痴呆症的胶体金试纸条及其制备方法
CN111763257B (zh) * 2020-09-01 2020-12-15 北京百奥赛图基因生物技术有限公司 抗gitr抗体及其用途
CN114920845A (zh) * 2020-12-31 2022-08-19 中元汇吉生物技术股份有限公司 特异性结合人IgG4的蛋白及其应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
EP0216846B2 (fr) 1985-04-01 1995-04-26 Celltech Limited Lignee cellulaire de myelomes transformee et procede d'expression d'un gene codant un polypeptide eucaryotique employant cette lignee
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP1400536A1 (fr) 1991-06-14 2004-03-24 Genentech Inc. Procédé pour fabriquer des anticorps humanisés
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
CA2372813A1 (fr) 1992-02-06 1993-08-19 L.L. Houston Proteine fixatrice biosynthetique pour marqueur du cancer
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
US6517529B1 (en) 1999-11-24 2003-02-11 Radius International Limited Partnership Hemodialysis catheter
US7618632B2 (en) * 2003-05-23 2009-11-17 Wyeth Method of treating or ameliorating an immune cell associated pathology using GITR ligand antibodies
WO2005047327A2 (fr) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Variants de polypeptide se liant au recepteur fc neonatal (fcrn), proteines de liaison fc dimeres et techniques associees
US20110123440A1 (en) 2005-03-29 2011-05-26 Genevieve Hansen Altered Antibody FC Regions and Uses Thereof
AU2006265936A1 (en) 2005-07-01 2007-01-11 Medimmune, Llc An integrated approach for generating multidomain protein therapeutics
KR101790802B1 (ko) * 2009-09-03 2017-10-27 머크 샤프 앤드 돔 코포레이션 항-ｇｉｔｒ 항체
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
SI3148579T1 (sl) * 2014-05-28 2021-07-30 Agenus Inc. Proti GITR antitelesa in postopki z njihovo uporabo
PE20170441A1 (es) 2014-06-06 2017-04-26 Bristol Myers Squibb Co Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus usos
WO2016115345A1 (fr) * 2015-01-14 2016-07-21 The Brigham And Women's Hospital, Traitement du cancer avec des anticorps monoclonaux anti-lap
EP3365371B1 (fr) 2015-10-22 2025-10-08 Ablynx NV Agonistes de gitr
EP3383431A4 (fr) 2015-12-02 2019-08-28 Agenus Inc. Anticorps anti-gitr et leurs méthodes d'utilisation
CN109563170B (zh) 2016-06-10 2023-10-13 瑞泽恩制药公司 抗gitr抗体及其用途
JP2019519536A (ja) 2016-07-01 2019-07-11 ファイブ プライム セラピューティクス， インコーポレイテッド Ｇｉｔｒアゴニストおよびｃｐｇを用いた組み合わせ抗腫瘍療法
WO2018031400A1 (fr) * 2016-08-12 2018-02-15 Janssen Biotech, Inc. Anticorps de membres de la superfamille anti-tnfr modifiés par fc ayant une activité agoniste améliorée et leurs procédés d'utilisation
CA3042727A1 (fr) * 2016-11-19 2018-05-24 Potenza Therapeutics, Inc. Proteines de liaison a un antigene anti-gitr et leurs procedes d'utilisation
EP3576793A4 (fr) 2017-02-06 2021-03-31 Dana Farber Cancer Institute, Inc. Compositions et méthodes pour augmenter la signalisation de récepteurs médiée par des anticorps
CA3054885A1 (fr) * 2017-03-03 2018-09-07 Rinat Neuroscience Corp. Anticorps anti-gitr et leurs methodes d'utilisation
TWI788340B (zh) * 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途

Also Published As

Publication number Publication date
CA3137822A1 (fr) 2020-10-29
PE20220144A1 (es) 2022-01-27
EP3964525A4 (fr) 2022-12-28
IL287531A (en) 2021-12-01
MY210018A (en) 2025-08-21
CN110903392B (zh) 2024-02-13
JOP20210286A1 (ar) 2021-10-24
BR112021021281A2 (pt) 2022-03-08
PY2018606A (es) 2023-09-15
KR20220010501A (ko) 2022-01-25
WO2020218951A2 (fr) 2020-10-29
EA202192907A1 (ru) 2022-01-25
US12410257B2 (en) 2025-09-09
WO2020218951A3 (fr) 2020-12-24
JP2022532991A (ja) 2022-07-21
JP7695200B2 (ja) 2025-06-18
RU2734432C1 (ru) 2020-10-16
UY38672A (es) 2020-10-30
CN110903392A (zh) 2020-03-24
CO2021014153A2 (es) 2021-10-29
US20220213209A1 (en) 2022-07-07
EP3964525A2 (fr) 2022-03-09
TW202100554A (zh) 2021-01-01
CL2021002792A1 (es) 2022-06-24
AU2020261207A1 (en) 2021-12-23
MA54969A1 (fr) 2022-08-31
MA55390B1 (fr) 2022-10-31
ZA202109374B (en) 2022-12-21
MX2021012962A (es) 2021-12-15
AR118763A1 (es) 2021-10-27
TWI803718B (zh) 2023-06-01
MA54969B2 (fr) 2025-10-31

Similar Documents

Publication Publication Date Title
MA55390B1 (fr) Dispositif pour découper l'adn à base de la protéine cas9 à partir de la bactérie pasteurella pneumotropica
MA53578A1 (fr) Dispositif pour découper l'adn à base de la protéine cas9 à partir de defluviimonas sp.
McDowell et al. Localised sequence regions possessing high melting temperatures prevent the amplification of a DNA mimic in competitive PCR
Dı́ez et al. Study of genetic diversity of eukaryotic picoplankton in different oceanic regions by small-subunit rRNA gene cloning and sequencing
Pan et al. Universal solvent quality crossover of the zero shear rate viscosity of semidilute DNA solutions
Tomas et al. Analysis of 12 X-STRs in greenlanders, danes and somalis using argus X-12
MA53577A1 (fr) Moyen de découpage d'adn à base de la protéine cas9 sur la base d'une bactérie à valeur biotechnologique clostridium cellulolyticum
MA30394B1 (fr) Synthese d'acylaminoalcenylene-amides pouvant etre employes en tant qu'antagonistes de la substance p
Carvalho et al. IL-17A and IL-17F polymorphisms in rheumatoid arthritis and Sjögren’s syndrome
WO2018140329A8 (fr) Méthodes de construction de copies de molécules d'acide nucléique
FR3034430A1 (fr) Lignee cellulaire surexprimant l'antigene cd303 humain
Camargo et al. Novel two-component system of Streptococcus sanguinis affecting functions associated with viability in saliva and biofilm formation
FR2981354B1 (fr) Copolymere dienique a au moins deux blocs, son procede de synthese et composition de caoutchouc le contenant
Ali et al. The genetic architecture of the MHC class II region in British Texel sheep
MA57032A1 (fr) Utilisation de beige cas9 issu de bactérie pasteurella pneumotropica
Pérez-Espona et al. First assessment of MHC diversity in wild Scottish red deer populations
Ferreira et al. Whole-genome mapping reveals a large chromosomal inversion on Iberian Brucella suis biovar 2 strains
WO2018194321A3 (fr) Nouveau composé à base de polyglycérol hyper-ramifié et composition cosmétique le contenant
FR3046416B1 (fr) Composes " multi-cibles " a activite inhibitrice des histone-desacetylases et de la polymerisation de la tubuline pour son utilisation dans le traitement du cancer
Ribas et al. Major histocompatibility complex class I chain‐related gene A polymorphism and linkage disequilibrium with HLA‐B alleles in Euro‐Brazilians
FR3079140B1 (fr) Composition prebiotique
FR2771422B1 (fr) Reactifs et methodes pour la detection de genes lies au complexe majeur d'histocompatibilite d'oiseaux d'elevage, tels que le poulet
Nielsen et al. ATXN2 with intermediate-length CAG/CAA repeats does not seem to be a risk factor in hereditary spastic paraplegia
Postovoitova et al. Molecular genetic evaluation of Ukrainian flax cultivar homogeneity based on intron length polymorphism of actin genes and microsatellite loci
Morais et al. Genetic portrait of Lisboa immigrant population from Cabo Verde with mitochondrial DNA analysis